Extracellular vesicles (EVs) are extracellular nanovesicles released by most normal and cancerous cell types and are believed to play a role in cell-cell communication by delivering their cargo of nucleic acids, proteins, and metabolites to recipient cells. EVs produced from tumors have significant roles in controlling molecular pathways in malignancies. Internalization of exosomes by tumor cells alters biological pathways and various cancer, including reprogramming of stromal cells, regulating the immune system, recreating the architecture of the extracellular matrix, and endowing tumor cells with drug-resistant characteristics. EVs are an attractive platform for cancer treatment. Recent discoveries in EV-biology will enable the development of novel, more effective, less invasive, and more personalized cancer treatments. Furthermore, there is an unmet need to bioengineer EVs to make them targeted and effective in cancer management. This special issue will deal with EVs' role in pathogenesis, diagnosis, therapeutic delivery, treatment, and theranostic applications in Cancer.
This project aims to integrate the most recent information about the role of EVs in cancer development, diagnostics, therapeutic delivery, therapy, and theranostic applications. Extracellular vesicles (EVs) are one of the perfect and inexpensive natural nanoparticles for drug delivery, even with or without being modified on the surface protein. A range of approaches is used to engineer EVs for various biomedical applications, especially disease diagnostic, therapeutic (drug, CRISPR, miRNA, etc.) delivery physiological state sensing, or alteration of actuation functions in tumor cells. However, it is vital to do more research to optimize EV characterization protocol, regulate large-scale EV production, and investigate surface display technology modified by specific proteins or peptides for drug delivery systems. Multiple clinical trials are underway, and exosome-based diagnostics are already on the market, indicating the significance of this field of study.
We invite original research articles, reviews, and opinion articles describing the role of Extracellular vesicles (EVs) in cancer development, diagnostics, and therapeutic delivery, therapy, and theranostic applications. The manuscripts will also highlight current and expected challenges and potential solutions or/and significant achievements for exosome isolation/processing, characterization and applications. Potential topics should be included but are not limited to:
• Methods of EV isolation, sources, processing, characterization, and EV bioengineering technology.
• Applications of EV in diagnosis, prognosis, and targeting tumor cells.
• EVs and CRISPR, Nanomaterials, theranostics, Nanoelectronics, Nanocoatings, Nanocomposites, Nanoplasmonics, and personalized medicine.
Extracellular vesicles (EVs) are extracellular nanovesicles released by most normal and cancerous cell types and are believed to play a role in cell-cell communication by delivering their cargo of nucleic acids, proteins, and metabolites to recipient cells. EVs produced from tumors have significant roles in controlling molecular pathways in malignancies. Internalization of exosomes by tumor cells alters biological pathways and various cancer, including reprogramming of stromal cells, regulating the immune system, recreating the architecture of the extracellular matrix, and endowing tumor cells with drug-resistant characteristics. EVs are an attractive platform for cancer treatment. Recent discoveries in EV-biology will enable the development of novel, more effective, less invasive, and more personalized cancer treatments. Furthermore, there is an unmet need to bioengineer EVs to make them targeted and effective in cancer management. This special issue will deal with EVs' role in pathogenesis, diagnosis, therapeutic delivery, treatment, and theranostic applications in Cancer.
This project aims to integrate the most recent information about the role of EVs in cancer development, diagnostics, therapeutic delivery, therapy, and theranostic applications. Extracellular vesicles (EVs) are one of the perfect and inexpensive natural nanoparticles for drug delivery, even with or without being modified on the surface protein. A range of approaches is used to engineer EVs for various biomedical applications, especially disease diagnostic, therapeutic (drug, CRISPR, miRNA, etc.) delivery physiological state sensing, or alteration of actuation functions in tumor cells. However, it is vital to do more research to optimize EV characterization protocol, regulate large-scale EV production, and investigate surface display technology modified by specific proteins or peptides for drug delivery systems. Multiple clinical trials are underway, and exosome-based diagnostics are already on the market, indicating the significance of this field of study.
We invite original research articles, reviews, and opinion articles describing the role of Extracellular vesicles (EVs) in cancer development, diagnostics, and therapeutic delivery, therapy, and theranostic applications. The manuscripts will also highlight current and expected challenges and potential solutions or/and significant achievements for exosome isolation/processing, characterization and applications. Potential topics should be included but are not limited to:
• Methods of EV isolation, sources, processing, characterization, and EV bioengineering technology.
• Applications of EV in diagnosis, prognosis, and targeting tumor cells.
• EVs and CRISPR, Nanomaterials, theranostics, Nanoelectronics, Nanocoatings, Nanocomposites, Nanoplasmonics, and personalized medicine.
